Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer

NCT00215644 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Cancer
Gastric Cancer

Interventions

DRUG: Matuzumab
DRUG: Epirubicin
DRUG: Cisplatin
DRUG: Capecitabine

Sponsor

Merck KGaA, Darmstadt, Germany